Is MRNA or PTCT more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% PTC Therapeutics -22.58% -362.45% -6.76%

Does the media favor MRNA or PTCT?

In the previous week, Moderna had 5 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for Moderna and 7 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.34 beat Moderna's score of 0.18 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ROIV or PTCT?

In the previous week, Roivant Sciences had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 7 mentions for PTC Therapeutics. Roivant Sciences' average media sentiment score of 1.31 beat PTC Therapeutics' score of 0.34 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, INSM or PTCT?

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 38.25 -$1.28B -$5.75 N/A PTC Therapeutics $1.73B 3.74 $682.64M -$2.33 N/A

Is INSM or PTCT more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% PTC Therapeutics -22.58% -362.45% -6.76%

Does the media prefer INSM or PTCT?

In the previous week, Insmed had 13 more articles in the media than PTC Therapeutics. MarketBeat recorded 20 mentions for Insmed and 7 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.93 beat PTC Therapeutics' score of 0.34 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 13 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BNTX or PTCT?

In the previous week, BioNTech had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for BioNTech and 7 mentions for PTC Therapeutics. BioNTech's average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.34 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PTCT or VTRS more profitable?

Viatris has a net margin of -2.04% compared to PTC Therapeutics' net margin of -22.58%. Viatris' return on equity of 19.04% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Viatris -2.04% 19.04% 7.62%

PTC Therapeutics (PTCT) Competitors

$78.01 -0.58 (-0.74%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$78.19 +0.18 (+0.24%)

As of 05:27 AM Eastern

Compare

PTCT vs. MRNA, ROIV, INSM, BNTX, and VTRS

Should you buy PTC Therapeutics stock or one of its competitors? MarketBeat compares PTC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PTC Therapeutics include Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does PTC Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

PTC Therapeutics has lower revenue, but higher earnings than Moderna. PTC Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.14	-$2.82B	-$8.15	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

Moderna presently has a consensus price target of $38.80, suggesting a potential downside of 34.78%. PTC Therapeutics has a consensus price target of $92.29, suggesting a potential upside of 18.30%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has a net margin of -22.58% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, Moderna had 5 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for Moderna and 7 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.34 beat Moderna's score of 0.18 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

PTC Therapeutics beats Moderna on 9 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Roivant Sciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,965.03	-$299.77M	-$0.60	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

In the previous week, Roivant Sciences had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 7 mentions for PTC Therapeutics. Roivant Sciences' average media sentiment score of 1.31 beat PTC Therapeutics' score of 0.34 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a net margin of -22.58% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential downside of 1.35%. PTC Therapeutics has a consensus target price of $92.29, suggesting a potential upside of 18.30%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Roivant Sciences and PTC Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Insmed presently has a consensus price target of $209.13, indicating a potential upside of 95.41%. PTC Therapeutics has a consensus price target of $92.29, indicating a potential upside of 18.30%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Insmed has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.25	-$1.28B	-$5.75	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

In the previous week, Insmed had 13 more articles in the media than PTC Therapeutics. MarketBeat recorded 20 mentions for Insmed and 7 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.93 beat PTC Therapeutics' score of 0.34 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a net margin of -22.58% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Summary

Insmed beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does PTC Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

BioNTech presently has a consensus price target of $129.13, suggesting a potential upside of 40.11%. PTC Therapeutics has a consensus price target of $92.29, suggesting a potential upside of 18.30%. Given BioNTech's higher probable upside, equities research analysts plainly believe BioNTech is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has a net margin of -22.58% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

PTC Therapeutics has lower revenue, but higher earnings than BioNTech. PTC Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, BioNTech had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 8 mentions for BioNTech and 7 mentions for PTC Therapeutics. BioNTech's average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.34 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats PTC Therapeutics on 12 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Viatris?

PTC Therapeutics (NASDAQ:PTCT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Viatris has a net margin of -2.04% compared to PTC Therapeutics' net margin of -22.58%. Viatris' return on equity of 19.04% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Viatris	-2.04%	19.04%	7.62%

79.9% of Viatris shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PTC Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

PTC Therapeutics presently has a consensus target price of $92.29, indicating a potential upside of 18.30%. Viatris has a consensus target price of $17.50, indicating a potential upside of 3.00%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, PTC Therapeutics had 7 more articles in the media than Viatris. MarketBeat recorded 7 mentions for PTC Therapeutics and 0 mentions for Viatris. PTC Therapeutics' average media sentiment score of 0.34 beat Viatris' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
PTC Therapeutics	Neutral
Viatris	Neutral

Summary

PTC Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.52B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-33.48	20.49	27.07	23.94
Price / Sales	3.74	300.33	512.71	90.33
Price / Cash	8.95	60.31	26.68	47.25
Price / Book	-30.47	7.92	10.63	6.14
Net Income	$682.64M	$23.81M	$3.60B	$331.74M
7 Day Performance	-0.06%	-1.09%	-1.24%	-1.82%
1 Month Performance	-1.23%	2.56%	1.09%	-1.45%
1 Year Performance	63.00%	42.16%	23.66%	16.32%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	3.388 of 5 stars	$78.01 -0.7%	$92.29 +18.3%	+63.8%	$6.52B	$1.73B	N/A	1,410	Analyst Forecast
MRNA Moderna	1.7362 of 5 stars	$67.01 -1.8%	$38.27 -42.9%	+90.3%	$27.09B	$1.94B	N/A	4,700	Analyst Forecast
ROIV Roivant Sciences	1.8589 of 5 stars	$34.51 -4.1%	$33.59 -2.7%	+197.6%	$25.87B	$8.26M	N/A	860
INSM Insmed	4.0861 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+4.3%	$25.06B	$606.42M	N/A	1,664	Analyst Forecast
BNTX BioNTech	4.3308 of 5 stars	$90.07 -1.6%	$129.13 +43.4%	-16.2%	$23.14B	$3.25B	N/A	7,807	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does PTC Therapeutics compare to Moderna?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Summary

How does PTC Therapeutics compare to Insmed?

Summary

How does PTC Therapeutics compare to BioNTech?

Summary

How does PTC Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does PTC Therapeutics compare to Moderna?

Which has higher valuation and earnings, MRNA or PTCT?

Do analysts rate MRNA or PTCT?

Is MRNA or PTCT more profitable?

Does the media favor MRNA or PTCT?

Which has more volatility and risk, MRNA or PTCT?

Do institutionals and insiders believe in MRNA or PTCT?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Which has more risk and volatility, ROIV or PTCT?

Which has stronger earnings & valuation, ROIV or PTCT?

Does the media favor ROIV or PTCT?

Is ROIV or PTCT more profitable?

Do insiders and institutionals believe in ROIV or PTCT?

Do analysts prefer ROIV or PTCT?

Summary

How does PTC Therapeutics compare to Insmed?

Do analysts rate INSM or PTCT?

Which has more risk and volatility, INSM or PTCT?

Which has better earnings & valuation, INSM or PTCT?

Does the media prefer INSM or PTCT?

Is INSM or PTCT more profitable?

Summary

How does PTC Therapeutics compare to BioNTech?

Do analysts rate BNTX or PTCT?

Is BNTX or PTCT more profitable?

Which has better earnings and valuation, BNTX or PTCT?

Do institutionals & insiders hold more shares of BNTX or PTCT?

Which has more risk and volatility, BNTX or PTCT?

Does the media favor BNTX or PTCT?

Summary

How does PTC Therapeutics compare to Viatris?

Is PTCT or VTRS more profitable?

Do institutionals & insiders have more ownership in PTCT or VTRS?

Which has stronger valuation and earnings, PTCT or VTRS?

Which has more risk and volatility, PTCT or VTRS?

Do analysts recommend PTCT or VTRS?

Does the media favor PTCT or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools